Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Islatravir + Ulonivirine once weekly in HIV-1 suppressed adults
NCT06891066Phase 2Active, not recruiting
- Sponsor
- Merck & Co.
- Start
- Apr 2025
- Primary completion
- Aug 2027
- Modality
- Small Molecules
- Countries
- 4
01
Overview
Phase 2, randomised, open-label trial of islatravir and ulonivirine in human immunodeficiency virus type 1 infection (HIV-1) (2 arms), sponsored by Merck & Co. Primary endpoints: Percentage of Participants With HIV-1 RNA ≥50 copies/mL at 24 weeks, Percentage of Participants who Experience an Adverse Event at 96 weeks and 1 more. Started Apr 2025; status: active, not recruiting.
02
Drugs
islatravirulonivirine
03
Conditions
human immunodeficiency virus type 1 infection (HIV-1)
Beyond the preview
Go deeper on NCT06891066.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06891066.